

## Validation Responsibility in Reprocessing of Dental Instruments

Instrument reprocessing is a critical component of an office's infection control protocols. It is essential for clinicians to follow the manufacturer's Instructions For Use Manual (IFU) of each device to minimize any risks of cross-contamination. Labeling regulations pertaining to medical devices are found in the Parts of Title 21 of the Code of Federal Regulations (CFR). The general labeling requirements for medical devices are contained in 21 CFR Part 801. These regulations specify the minimum requirements for all devices. In this session, we will discuss the General Labeling Provisions in the Code of Federal Regulation pertaining to medical devices, adequate directions for use and its exemption, and its application in medical device reprocessing Instructions for Use. We will also review the process a manufacturer follows to develop usable validated reprocessing instructions for the reuse of medical devices.

### LEARNING OBJECTIVES:

1. Describe steps the manufacturer follows to develop validated reprocessing instructions
2. Apply knowledge of manufacturers IFU validation processes and the importance of following IFU's for medical devices in infection prevention training for dental office team members
3. Review the definition of Medical Device Labeling
4. Identify the General Labeling Provisions for medical devices found Parts of Title 21 of the Code of Federal Regulations (CFR), 21 CFR Part 801.
5. Recognize the elements of comprehensive reprocessing instructions per the FDA Guidance Document "Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling" issued March 17, 2015.

## CONTINUING EDUCATION

**CE CREDITS:** 1

**EDUCATIONAL METHOD:** Lecture, Recorded, Self-instructional (self-study)

**LOCATION:** Online

**ORIGINAL RELEASE DATE:** June 2022

**EXPIRATION DATE:** June 30, 2025

### RECOGNITION STATEMENT

**ADA CERP**® | Continuing Education  
Recognition Program

OSAP is an ADA CERP Recognized Provider.

ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

Concerns or complaints about a CE provider may be directed to the provider or to the **Commission for Continuing Education Provider Recognition** at [ADA.org/CERP](http://ADA.org/CERP).

Please email the OSAP office at [office@osap.org](mailto:office@osap.org) or call +1 (410) 571-0003 if you wish to be in contact with the course author/creator(s) with any questions or for clarification of course concepts or for technical assistance in completing the online test.

All participants assume individual responsibility for providing evidence of contact hours of continuing education to the appropriate authorities and for the maintenance of their individual records.

[See more details about OSAP's CE Program & Provider Recognition.](#)

**DISCLOSURE:**

All participating faculty are expected to disclose to the audience any significant financial interest or other relationship with:

1. the manufacturer of any commercial products and/or provider of commercial services discussed in an educational presentation and
2. any commercial supporters of the activity.

**CE DISCLAIMER:**

The 2022 OSAP Annual Conference is planned and presented by the 2022 OSAP Annual Conference Planning Committee to provide participants with a relevant and rewarding continuing educational experience. However, neither the content of a course nor the use of specific products in lectures or workshops should be construed as indicating endorsement or approval by OSAP of the views presented or the products used.

Speakers and authors of CE activities are required to present a balanced view of therapeutic options, use generic names of products whenever possible, use images that have not been falsified or misrepresent the outcome of treatment, and refrain from marketing or promoting any products or commercial services. Speakers and authors are required to include peer-reviewed content supported by generally accepted scientific principles or methods that can be substantiated or supported with peer-reviewed scientific literature that is relevant and current. Speakers and authors must support clinical recommendations with references from the scientific literature, with a sound scientific basis, whenever possible. Speakers and authors of CE activities are required to disclose to participants any financial, commercial, or promotional interest in a product or company that may influence their presentations. However, OSAP shall not be liable for a speaker's failure to disclose such interest.

**SPEAKERS:**

**David Kierce**  
**SENIOR GLOBAL PRODUCT MANAGER**  
**Dentsply Sirona**

Mr. Kierce is the Senior Global Product Manager for the Infection Prevention, Scaling and Diagnostic Platform for Dentsply Sirona. He is responsible for new product development in all global markets. He has been with Dentsply Sirona for 29 years holding various sales and marketing positions with increased responsibilities. Prior to joining Dentsply Sirona, he held positions at GMAC and Kraft General Foods.

**Disclosures:** Stock Shareholder - Dentsply Sirona

**Lauren Giles, RAC**  
**BIOMEDICAL ENGINEER**  
**FDA**

Ms. Giles is a Biomedical Engineer in the Dental and ENT Division of OHT1 serving as a lead scientific reviewer since joining the FDA in 2011. Ms. Giles received a Bachelor of Science degree in Biomedical Engineering in 2009 from Georgia Institute of Technology and received her Regulatory Affairs

Certification (RAC) in 2017. As a member of the Dental Devices Branch, Ms. Giles has focused her career on the review of dental handpieces, dental operative units, and dental stereotaxic devices. Ms. Giles represents the FDA as a liaison for SubCommittee 4 Dental Instruments for both the American Dental Association Standards for Dental Products and ISO TC 106 Dentistry.

**Disclosures:** No relevant financial relationships to disclose.